Journal Issue 2 | GU Oncology Now

GU Oncology Now Journal Issue 2

GU Oncology Now Journal Issue 2

Special ASCO GU Cancers Conference Coverage

Cover Story

Interview With Dr. Bital Savir-Baruch on the TheraP Study: 177Lu-PSMA-617 Versus Cabazitaxel in mCRPC Phase 3 Trial

ASCO GU Cancers Conference Coverage - Prostate Cancer

Enzalutamide Provides Similar Clinical Benefit in Men With Metastatic Hormone-Sensitive Prostate Cancer With Either De Novo Disease or Disease Progression

177Lu-PSMA-617 Improves Progression-Free Survival and Patient-Reported Outcomes Compared With Cabazitaxel for Men With Metastatic Castration-Resistant Prostate Cancer

Circulating Tumor Cell Counts Associated With Prognosis and Response in Men Receiving Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer

ASCO GU Cancers Conference Coverage - Kidney Cancer

Dr. William G. Kaelin, Jr. on von Hippel-Lindau Disease in Kidney Cancer and Treatments in Keynote

Cabozantinib Improves Progression-Free Survival Versus Sunitinib in Patients With Metastatic pRCC in SWOG 1500

Lenvatinib Plus Pembrolizumab Improves Overall Survival Compared With Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma in the CLEAR Trial

ASCO GU Cancers Conference Coverage - Bladder Cancer

Adjuvant Nivolumab Improves Disease-Free Survival for Patients With Muscle-Invasive Urothelial Carcinoma in CheckMate 274

Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients With Advanced Urothelial Carcinoma in the EV-301 Trial

Environmental Factors Affecting Risk of Urothelial Carcinoma

GU Oncology Now Journal Issue 2